Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for OSA in PAP Non-Adherent Patients
NCT04205136Phase 4Withdrawn
- Sponsor
- University of Michigan
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of spironolactone in obstructive sleep apnea (OSA), sponsored by University of Michigan. Planned start Mar 2022; status: withdrawn.
02
Drugs
spironolactone
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04205136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205136.